PRIVIA HEALTH GROUP INC (PRVA) Stock Fundamental Analysis
NASDAQ:PRVA - Nasdaq - US74276R1023 - Common Stock - Currency: USD
PRVA gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 109 industry peers in the Health Care Providers & Services industry. While PRVA has a great health rating, its profitability is only average at the moment. While showing a medium growth rate, PRVA is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
PRVA had positive earnings in the past year.
PRVA had a positive operating cash flow in the past year.
In multiple years PRVA reported negative net income over the last 5 years.
Each year in the past 5 years PRVA had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 1.12%, PRVA is in line with its industry, outperforming 57.41% of the companies in the same industry.
PRVA has a Return On Equity of 2.09%. This is in the better half of the industry: PRVA outperforms 60.19% of its industry peers.
PRVA has a Return On Invested Capital of 1.43%. This is comparable to the rest of the industry: PRVA outperforms 42.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.12% | ||
| ROE | 2.09% | ||
| ROIC | 1.43% |
ROA(3y)-8.73%
ROA(5y)-2.74%
ROE(3y)-13.9%
ROE(5y)-2.6%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PRVA has a Profit Margin of 0.75%. This is comparable to the rest of the industry: PRVA outperforms 58.33% of its industry peers.
In the last couple of years the Profit Margin of PRVA has declined.
PRVA has a Operating Margin of 0.77%. This is in the lower half of the industry: PRVA underperforms 60.19% of its industry peers.
In the last couple of years the Operating Margin of PRVA has grown nicely.
PRVA has a worse Gross Margin (9.78%) than 78.70% of its industry peers.
PRVA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.77% | ||
| PM (TTM) | 0.75% | ||
| GM | 9.78% |
OM growth 3Y-26.28%
OM growth 5Y30.07%
PM growth 3Y-28.56%
PM growth 5YN/A
GM growth 3Y-1.22%
GM growth 5Y2.55%
2. Health
2.1 Basic Checks
PRVA has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
PRVA has more shares outstanding than it did 1 year ago.
There is no outstanding debt for PRVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
PRVA has an Altman-Z score of 4.81. This indicates that PRVA is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of PRVA (4.81) is better than 84.26% of its industry peers.
There is no outstanding debt for PRVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.81 |
ROIC/WACC0.16
WACC9.18%
2.3 Liquidity
A Current Ratio of 1.78 indicates that PRVA should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.78, PRVA is in the better half of the industry, outperforming 65.74% of the companies in the same industry.
A Quick Ratio of 1.78 indicates that PRVA should not have too much problems paying its short term obligations.
With a decent Quick ratio value of 1.78, PRVA is doing good in the industry, outperforming 68.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.78 | ||
| Quick Ratio | 1.78 |
3. Growth
3.1 Past
PRVA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -67.74%.
The earnings per share for PRVA have been decreasing by -14.87% on average. This is quite bad
The Revenue has grown by 8.53% in the past year. This is quite good.
Measured over the past years, PRVA shows a very strong growth in Revenue. The Revenue has been growing by 20.31% on average per year.
EPS 1Y (TTM)-67.74%
EPS 3Y-14.87%
EPS 5YN/A
EPS Q2Q%-40%
Revenue 1Y (TTM)8.53%
Revenue growth 3Y26.59%
Revenue growth 5Y20.31%
Sales Q2Q%2.27%
3.2 Future
PRVA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.91% yearly.
Based on estimates for the next years, PRVA will show a small growth in Revenue. The Revenue will grow by 1.11% on average per year.
EPS Next Y-29.67%
EPS Next 2Y17.38%
EPS Next 3Y24.91%
EPS Next 5YN/A
Revenue Next Year3.43%
Revenue Next 2Y7.4%
Revenue Next 3Y8.96%
Revenue Next 5Y1.11%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
PRVA is valuated quite expensively with a Price/Earnings ratio of 231.70.
Compared to the rest of the industry, the Price/Earnings ratio of PRVA is on the same level as its industry peers.
PRVA's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.47.
PRVA is valuated quite expensively with a Price/Forward Earnings ratio of 88.50.
The rest of the industry has a similar Price/Forward Earnings ratio as PRVA.
The average S&P500 Price/Forward Earnings ratio is at 92.74. PRVA is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 231.7 | ||
| Fwd PE | 88.5 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PRVA is valued a bit more expensive than the industry average as 60.19% of the companies are valued more cheaply.
Based on the Price/Free Cash Flow ratio, PRVA is valued a bit cheaper than 67.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 28.21 | ||
| EV/EBITDA | 114.23 |
4.3 Compensation for Growth
A more expensive valuation may be justified as PRVA's earnings are expected to grow with 24.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.38%
EPS Next 3Y24.91%
5. Dividend
5.1 Amount
No dividends for PRVA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PRIVIA HEALTH GROUP INC
NASDAQ:PRVA (2/4/2025, 8:02:35 PM)
After market: 23.17 0 (0%)23.17
+0.27 (+1.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners95.75%
Inst Owner Change-0.2%
Ins Owners6.07%
Ins Owner Change1.98%
Market Cap2.78B
Analysts84.83
Price Target26.79 (15.62%)
Short Float %5.34%
Short Ratio9.98
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-37.5%
Min EPS beat(2)-38.73%
Max EPS beat(2)-36.27%
EPS beat(4)0
Avg EPS beat(4)-46.87%
Min EPS beat(4)-58.84%
Max EPS beat(4)-36.27%
EPS beat(8)3
Avg EPS beat(8)79.35%
EPS beat(12)6
Avg EPS beat(12)87.76%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.26%
Min Revenue beat(2)1.03%
Max Revenue beat(2)1.48%
Revenue beat(4)4
Avg Revenue beat(4)2.7%
Min Revenue beat(4)1.03%
Max Revenue beat(4)6.03%
Revenue beat(8)6
Avg Revenue beat(8)-3.55%
Revenue beat(12)6
Avg Revenue beat(12)-14.8%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.04%
PT rev (3m)3.08%
EPS NQ rev (1m)0.1%
EPS NQ rev (3m)-8.31%
EPS NY rev (1m)-0.6%
EPS NY rev (3m)-11.4%
Revenue NQ rev (1m)0.2%
Revenue NQ rev (3m)-1.13%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)0.89%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 231.7 | ||
| Fwd PE | 88.5 | ||
| P/S | 1.62 | ||
| P/FCF | 28.21 | ||
| P/OCF | 28.2 | ||
| P/B | 4.52 | ||
| P/tB | 7.47 | ||
| EV/EBITDA | 114.23 |
EPS(TTM)0.1
EY0.43%
EPS(NY)0.26
Fwd EY1.13%
FCF(TTM)0.82
FCFY3.55%
OCF(TTM)0.82
OCFY3.55%
SpS14.3
BVpS5.12
TBVpS3.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.12% | ||
| ROE | 2.09% | ||
| ROCE | 1.97% | ||
| ROIC | 1.43% | ||
| ROICexc | 3.9% | ||
| ROICexgc | 607.85% | ||
| OM | 0.77% | ||
| PM (TTM) | 0.75% | ||
| GM | 9.78% | ||
| FCFM | 5.74% |
ROA(3y)-8.73%
ROA(5y)-2.74%
ROE(3y)-13.9%
ROE(5y)-2.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y-29.21%
ROICexc growth 5YN/A
OM growth 3Y-26.28%
OM growth 5Y30.07%
PM growth 3Y-28.56%
PM growth 5YN/A
GM growth 3Y-1.22%
GM growth 5Y2.55%
F-Score5
Asset Turnover1.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 59.25 | ||
| Cash Conversion | 484.16% | ||
| Profit Quality | 768.61% | ||
| Current Ratio | 1.78 | ||
| Quick Ratio | 1.78 | ||
| Altman-Z | 4.81 |
F-Score5
WACC9.18%
ROIC/WACC0.16
Cap/Depr(3y)8.76%
Cap/Depr(5y)89.83%
Cap/Sales(3y)0.02%
Cap/Sales(5y)0.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-67.74%
EPS 3Y-14.87%
EPS 5YN/A
EPS Q2Q%-40%
EPS Next Y-29.67%
EPS Next 2Y17.38%
EPS Next 3Y24.91%
EPS Next 5YN/A
Revenue 1Y (TTM)8.53%
Revenue growth 3Y26.59%
Revenue growth 5Y20.31%
Sales Q2Q%2.27%
Revenue Next Year3.43%
Revenue Next 2Y7.4%
Revenue Next 3Y8.96%
Revenue Next 5Y1.11%
EBIT growth 1Y-38.53%
EBIT growth 3Y-6.67%
EBIT growth 5Y56.49%
EBIT Next Year268.6%
EBIT Next 3Y74.46%
EBIT Next 5Y51.29%
FCF growth 1Y1698.65%
FCF growth 3Y27.95%
FCF growth 5Y74.19%
OCF growth 1Y1623.58%
OCF growth 3Y27.59%
OCF growth 5Y72.76%